Skip to content
yes i take peptides.
Library/For Energy/EPO (Erythropoietin)
FDA Approved⚠ WADA Banned+2 more

EPO (Erythropoietin)

Recombinant human erythropoietin. We read all 60 studies. The protocol is below.

Updated 03 May 2026Read 13 minEvidence ●●●●●Citations 60
+ Add to Stack
⚖ Compare side-by-side⎙ Print companion card

Free — puts EPO (Erythropoietin) on your decision board.

The EPO (Erythropoietin) Report · $19

Everything you need to start: dose, sourcing, safety, our verdict.

One purchase · yours forever

Built from 60 cited studies.

Status
FDA
Class
WADA Banned
Evidence
5/ 5●●●●●
FDA approval (Epogen)
Jun 1989
Approved indications
$19 ↓
WADA status
$19 ↓
⚠ WADA
Read this if
  • you have CKD anemia or chemo-induced anemia and your doctor is talking about Procrit
  • you're an endurance athlete trying to understand why this is the most famous doping story in sports
  • a "longevity clinic" offered to inject you with EPO and you want to know what you're agreeing to
  • you're being told EPO "didn't work" — iron, B12, and folate are the substrates EPO needs; without them stocked, the marrow can't build red cells no matter how loud the signal is
Skip this if
  • you're looking for a healthy-adult performance hack — athletes have died doing this
  • you have active cardiovascular disease, prior stroke, or a clotting disorder
  • you compete in any tested sport — it's the original WADA flag
The 4 ways you can buy EPO (Erythropoietin)
Brand
✗
No FDA approval
Compounded 503A
✗
Not available
Cannot be compounded — EPO is a recombinant biologic.
RUO (research-only)
✗
Not available
Not meaningfully available
Listings exist but are typically gray repackaged or counterfeit, not RUO.
Gray market
✓
Illegal; black-market route
Varies — not on user's vendor list (~$150–$500 historically)
Counterfeit common. Athlete deaths documented. Pricing volatile and unverified.
Click any lane for the full Sourcing breakdown.
First 90 days · EPO (Erythropoietin)
Weeks 1–2
Sleep depth shifts within days for the GH-secretagogue class (CJC, ipamorelin, sermorelin, hexarelin). If sleep hasn't deepened by week 2, the rest of the protocol probably won't move either.
Weeks 4–8
Subjective recovery and energy improvements. Body composition shifts modestly — slight muscle gain, slight fat loss if diet allows.
Week 12 — decide
Bloodwork: IGF-1 is the objective check. If IGF-1 hasn't moved, the protocol isn't working at this dose. Side effect bookkeeping: water retention, joint stiffness, any glucose changes.
Quit if
  • IGF-1 climbs above ~300 ng/mL (cancer-risk territory at the upper end).
  • Significant water retention or new carpal-tunnel-style symptoms.
  • New or worsening insulin resistance (fasting glucose creep).
  • 12 weeks with no IGF-1 movement and no subjective change.
Identity

What it is.

EPO is erythropoietin, a 165-amino-acid glycoprotein hormone made primarily by the kidneys. It tells the bone marrow to produce more red blood cells. More red cells mean more oxygen-carrying capacity in the blood.

The recombinant version was one of the first major biotech blockbusters — approved by the FDA in 1989 as Epogen (Amgen) and Procrit (Johnson & Johnson). Longer-acting analogs followed: Aranesp (darbepoetin), Mircera. It's standard care for the anemia of chronic kidney disease and for chemotherapy-induced anemia.

It's also the most famous blood doping drug in sports history — the Lance Armstrong era of professional cycling ran on it. WADA-banned in and out of competition. Detection methods now exist but lag the dosing protocols.

Prescription only. The off-label market is essentially black.

TL;DR

TL;DR. 30-second version.

The compressed verdict — what EPO (Erythropoietin) actually is, what the human evidence shows, and the watch-for in three bullets. Locked.

Get the report · $19 ↓
Mechanism

Mechanism.

Mechanism · in the EPO (Erythropoietin) report

How the molecule actually works — receptor profile, downstream signaling, what to expect mechanistically.

Get the report · $19 ↓
Evidence

Evidence. What we actually know in humans.

Evidence · in the EPO (Erythropoietin) report

The trial breakdown — phase, n, primary endpoint, who funded, what hit, what didn't.

Get the report · $19 ↓
Human-Evidence Factbox
FDA approval (Epogen)
Jun 1989
Approved indications
$19 ↓
WADA status
$19 ↓
Black box warning
$19 ↓
Target hemoglobin (CKD)
$19 ↓
Off-label endurance use
$19 ↓
Required substrates (KDIGO 2012)
$19 ↓
Iron deficiency on EPO (esp. CKD)
$19 ↓
Dose

Dose. The actual protocol.

Dose · in the EPO (Erythropoietin) report

The specific protocol — dose, titration schedule, cycle pattern, frequency, route.

We read 60 studies to write this report.
Get the report · $19 ↓
Sourcing

Sourcing. Where the cohort actually buys.

Sourcing · in the EPO (Erythropoietin) report

Sourcing breakdown — vendor methodology, red flags, our published test results, COA checklist.

We read 60 studies to write this report.
Get the report · $19 ↓
Safety

Safety. Side effects.

Safety · in the EPO (Erythropoietin) report

The watch-for list — contraindications, drug interactions, monitoring labs, when to stop.

Get the report · $19 ↓
Editorial Position

Editorial position.

Editorial Position · in the EPO (Erythropoietin) report

Our editorial position — explicit yes / no / depends, with the reasoning behind it.

Get the report · $19 ↓
Citations

Citations.

  1. 01LANGE RD, et al. ERYTHROPOIETIN. Progress in hematology. 1964;4:72-96. PMID: 14274541.
  2. 02GRISMONDI GL. [ERYTHROPOIETIN]. Attualita di ostetricia e ginecologia. 1964;10:959-75. PMID: 14305334.
  3. 03ACHESON ED. ERYTHROPOIETIN. British medical journal. 1964;1(5390):1060-1. PMID: 14113813.
  4. 04BUSOVA B. [ERYTHROPOIETIN]. Lekarsky obzor. 1964;13:113-20. PMID: 14126344.
  5. 05GOELTNER E. [ERYTHROPOIETIN IN PREGNANCY AND AFTER LABOR]. Archiv fur Gynakologie. 1964;200:60-87. PMID: 14299427.
+Show all 60 citations
  1. 06Ehrenreich H, et al. Erythropoietin in Preterm Infants. The New England journal of medicine. 2020;382(19):1862. PMID: 32374968.
  2. 07Mariotti C, et al. Erythropoietin in Friedreich ataxia. Journal of neurochemistry. 2013;126 Suppl 1:80-7. PMID: 23859343.
  3. 08Adamson J. Erythropoietin, iron metabolism, and red blood cell production. Seminars in hematology. 1996;33(2 Suppl 2):5-7; discussion 8-9. PMID: 8723573.
  4. 09SACKS MS. Erythropoietin. Annals of internal medicine. 1958;48(1):207-12. PMID: 13488231.
  5. 10Juul SE, et al. Erythropoietin in Preterm Infants. Reply. The New England journal of medicine. 2020;382(19):1862-1863. PMID: 32374969.
  6. 11Bieber E. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview. The Journal of reproductive medicine. 2001;46(5 Suppl):521-30. PMID: 11396386.
  7. 12Aher SM, et al. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. The Cochrane database of systematic reviews. 2020;2(2):CD004865. PMID: 32048729.
  8. 13Zitella L. Erythropoietin-stimulating agents: new data yield new insights. Oncology (Williston Park, N.Y.). 2007;21(11 Suppl Nurse Ed):36-8. PMID: 18154208.
  9. 14ROSE JC. Erythropoietin. GP. 1958;17(1):81-2. PMID: 13490653.
  10. 15Jin X, et al. Erythropoietin alleviates lung ischemia-reperfusion injury by activating the FGF23/FGFR4/ERK signaling pathway. PeerJ. 2024;12:e17123. PMID: 38560469.
  11. 16DE RITIS G. [Erythropoietin]. Annali dell'Istituto "Carlo Forlanini". 1962;22:99-105. PMID: 13884489.
  12. 17MARINESCU S, et al. [Erythropoietin]. Medicina interna. 1961;13:1351-3. PMID: 14469874.
  13. 18Donadei C, et al. Erythropoietin inhibits SGK1-dependent TH17 induction and TH17-dependent kidney disease. JCI insight. 2019;5(10). PMID: 31013255.
  14. 19Weiss MJ. New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications. The oncologist. 2003;8 Suppl 3:18-29. PMID: 14671225.
  15. 20Warrillow SJ. Erythropoietin use in the critically ill: current evidence. Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine. 2008;10(3):257-60. PMID: 18798726.
  16. 21Sfacteria A. Insights into erythropoietin in veterinary oncology: The other side of the coin. Veterinary journal (London, England : 1997). 2015;206(3):247-8. PMID: 26526865.
  17. 22Walker RG. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?. Clinical journal of the American Society of Nephrology : CJASN. 2008;3(4):935-7. PMID: 18579671.
  18. 23Yanagawa T, et al. Sufficient liver erythropoietin synthesis is induced in hemodialysis patients not requiring erythropoiesis-stimulating agents. Clinical nephrology. 2022;98(3):167-170. PMID: 35818816.
  19. 24ERSLEV AJ. THE ROLE OF ERYTHROPOIETIN IN THE CONTROL OF RED CELL PRODUCTION. Medicine. 1964;43:661-5. PMID: 14226581.
  20. 25Kaufman JS. Racial differences in erythropoietin responsiveness. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2008;52(6):1035-8. PMID: 19026356.
  21. 26Ford PA, et al. Strategies to optimize the use of erythropoietin and iron therapy in oncology patients. Transfusion. 2004;44(12 Suppl):15S-25S. PMID: 15585001.
  22. 27Feusner J, et al. Recombinant human erythropoietin in pediatric oncology: a review. Medical and pediatric oncology. 2002;39(4):463-8. PMID: 12203665.
  23. 28DA COSTA H, et al. Erythropoietin, current concept. Indian journal of medical sciences. 1963;17:132-7. PMID: 14024555.
  24. 29PLZAK LF Jr. Erythropoietin-a renal hormone. Surgical forum. 1960;10:121-4. PMID: 14433547.
  25. 30Macdougall IC. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another. Current medical research and opinion. 2004;20(1):83-6. PMID: 14741076.
  26. 31EBIHARA T, et al. [ERYTHROPOIETIN--ERYTHROCYTE-STIMULATING FACTOR (2)]. Showa Igakkai zasshi = The Journal of the Showa Medical Association. 1963;23:323-9. PMID: 14157121.
  27. 32Peces R. [Pure red cell aplasia and antibodies against erythropoietin. Doubts still remain]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 2003;23(4):295-6, 297. PMID: 14558327.
  28. 33Adamson JW, et al. Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer. Oncology. 1999;56(1):46-53. PMID: 9885377.
  29. 34De Luisi A, et al. Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma. Angiogenesis. 2013;16(4):963-73. PMID: 23881169.
  30. 35MONTI G. [THE RENAL CONTROL OF HEMOPOIESIS: ERYTHROPOIETIN]. Il Policlinico. Sezione medica. 1963;70:307-23. PMID: 14119016.
  31. 36Edwards JK. Anaemia: Regulation of renal erythropoietin via HIF. Nature reviews. Nephrology. 2016;12(5):256. PMID: 26973079.
  32. 37WHITE WF, et al. Studies on erythropoietin. Recent progress in hormone research. 1960;16:219-62. PMID: 13844409.
  33. 38NAKAO K. Studies on erythropoietin. Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society. 1962;25:253-79. PMID: 13937478.
  34. 39GURNEY CW. Erythropoietin, erythropoiesis, and the kidney. JAMA. 1960;173:1828-9. PMID: 13830370.
  35. 40Bradbury J. Erythropoietin helps children with cancer-related anaemia. The Lancet. Oncology. 2006;7(9):713. PMID: 16981303.
  36. 41COTES PM. Erythropoietin and the physiological control of erythropoiesis. Proceedings of the Royal Society of Medicine. 1961;54(5):371-4. PMID: 13695858.
  37. 42Bejder J, et al. Detection of erythropoietin misuse by the Athlete Biological Passport combined with reticulocyte percentage. Drug testing and analysis. 2016;8(10):1049-1055. PMID: 27696774.
  38. 43RAMBACH WA, et al. The nature of erythropoietin. Annals of the New York Academy of Sciences. 1959;77:623-6. PMID: 14436017.
  39. 44MIRAND EA. ERYTHROPOIETIN STUDIES IN TAMARINS. Laboratory animal care. 1965;15:131-9. PMID: 14319534.
  40. 45D'Ambra MN, et al. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. The Annals of thoracic surgery. 1997;64(6):1686-93. PMID: 9436556.
  41. 46Macdougall IC. Biosimilar epoetins. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2009;24(5):1698-9; author reply 1699-700. PMID: 19366858.
  42. 47Guarienti M, et al. Computational and functional analysis of biopharmaceutical drugs in zebrafish: Erythropoietin as a test model. Pharmacological research. 2015;102:12-21. PMID: 26361727.
  43. 48LOWY PH, et al. Inactivation of erythropoietin by neuraminidase and by mild substitution reactions. Nature. 1960;185:102-3. PMID: 14418589.
  44. 49KELLER HM. [ERTHROPOIETIN]. Schweizerische medizinische Wochenschrift. 1964;94:1773-8. PMID: 14339495.
  45. 50GUTNISKY A, et al. STIMULATION OF ERYTHROPOIETIN PRODUCTION BY WHOLE-BODY IRRADIATION (SPLEEN SHIELDED). Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1964;5:595-605. PMID: 14212185.
  46. 51FURUYA H. [Erythropoietin-endocrine regulation of hematopoiesis]. [Sanfujinka chiryo] Obstetrical and gynecological therapy. 1961;28:739-49. PMID: 13702709.
  47. 52ROSSE WF, et al. Renal cysts, erythropoietin and polycythemia. The American journal of medicine. 1963;34:76-81. PMID: 13975141.
  48. 53Banaei S, et al. Combination Anti-Apoptotic Effect of Erythropoietin and Melatonin on Ischemia Reperfusion-Induced Renal Injury in Rats. Acta medica Iranica. 2016;54(10):624-630. PMID: 27888589.
  49. 54Park SS, et al. Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. Journal of pharmaceutical sciences. 2009;98(5):1688-99. PMID: 18781649.
  50. 55Cowper B, et al. Glycan analysis of erythropoiesis-stimulating agents. Journal of pharmaceutical and biomedical analysis. 2020;180:113031. PMID: 31838284.
  51. 56Olsen NV. Central nervous system frontiers for the use of erythropoietin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2003;37 Suppl 4:S323-30. PMID: 14582001.
  52. 57DONATI RM, et al. NEPHROGENIC ERYTHROCYTOSIS. Archives of internal medicine. 1963;112:960-5. PMID: 14065007.
  53. 58— Counterfeit Procrit. FDA consumer. 2003;37(3):5. PMID: 12793379.
  54. 59Grampp G, et al. Structure-Function Relationships for Recombinant Erythropoietins: A Case Study From a Proposed Manufacturing Change With Implications for Erythropoietin Biosimilar Study Designs. Journal of pharmaceutical sciences. 2018;107(6):1512-1520. PMID: 29408510.
  55. 60ALTHOFF H. [ON THE CLINICAL SIGNIFICANCE OF ERYTHROPOIETIN]. Annales Nestle. [Deutsche Aufl.]. 1963;20:34-8. PMID: 14089326.
The EPO (Erythropoietin) Report · $19

Everything you need to start.

Dose, sourcing, safety, our verdict. One purchase. Yours forever.

Built from 60 cited studies.

Or get every report. All reports — $99 once · Pro — $29/mo.
Compare tiers →